Devodil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Devodil

Property Description
Active ingredient Sulpiride
Form Tablets, Capsules, Oral Solution, Intramuscular Injection
Pharmacological class Atypical Antipsychotic / Neuroleptic
Origin Synthetic (Chemically synthesized)
Product type Single-ingredient product

Devodil: Defining the Atypical Antipsychotic Class

Devodil is a commercial medicinal product containing the active ingredient Sulpiride, a substituted benzamide derivative classified pharmacologically as an atypical antipsychotic agent. It is a synthetic small molecule drug that functions as a neuroleptic, primarily used under prescription only status. This specific product is typically recognized across international markets for offering a comprehensive range of dosage forms.

The classification of Sulpiride as an atypical antipsychotic reflects a distinct pharmacological profile focused on specific receptors within the central nervous system. Its established role is in stabilizing severe disturbances in mental functioning and emotional regulation.

Sulpiride's Available Forms and General Purpose

The active component, Sulpiride (chemical formula C15H23N3O4S), is supplied in several pharmaceutical preparations, including tablets and capsules for oral use, a liquid oral solution suitable for flexible dosing, and sterile solutions designated for intramuscular injection. The availability of both oral and parenteral routes of administration is essential for addressing both routine and acute patient needs.

The core purpose of this medicine is to promote stability by acting as a selective dopamine D2 and D3 antagonist (or blocker), thereby adjusting the activity of dopamine in the brain. This action defines its therapeutic potential in alleviating significant mental and emotional dysregulation, which is the general function of this type of neuroleptic intervention.

What side effects are possible with Devodil?

Adverse Effects Profile

Devodil's safety information is based on governmental regulatory documents, which classify adverse events by frequency and system-organ class.

Common Adverse Reactions (Affecting up to 1 in 10 people)

Commonly reported side effects primarily affect the endocrine and nervous systems. These include:

  • Hyperprolactinaemia: An increase in the hormone prolactin, which may lead to breast pain, abnormal milk secretion, or changes in the menstrual cycle in women.
  • Nervous System Effects: Drowsiness, sedation, insomnia, tremors, or extrapyramidal disorders (such as parkinsonism, characterized by muscle stiffness, shuffling, or involuntary movements).
  • Other Common Effects: Weight gain, constipation, and maculo-papular rash.

Serious and Rare Adverse Reactions (Rarely affecting up to 1 in 1,000 people or frequency not known)

Regulatory texts note several serious risks, some of which require immediate medical attention:

  • Neuroleptic Malignant Syndrome (NMS): A rare, potentially life-threatening reaction marked by high fever, severe muscle stiffness, confusion, and irregular heart rate or blood pressure.
  • Cardiac Events: Prolongation of the QT interval (a measure of heart rhythm on ECG), ventricular arrhythmias, or cardiac arrest.
  • Thromboembolism: The formation of blood clots in the veins, such as deep vein thrombosis (DVT), which can lead to pulmonary embolism.
  • Hematological Disorders: Blood dyscrasias like agranulocytosis (a serious decrease in white blood cells), which can increase the risk of infection.
  • Seizures and Anaphylactic Reactions (severe allergic reactions) have also been reported.

Safety Considerations and Restrictions

Population-Specific Caution: The drug requires caution in specific patient groups. A dose reduction may be necessary for individuals with kidney impairment. It is generally not recommended during pregnancy or for patients with pre-existing conditions such as Parkinson's disease, epilepsy, or certain cardiovascular disorders due to safety concerns. Elderly patients, particularly those with high blood pressure, should also be monitored carefully.

Limitations of Use: Regulatory information contraindicates the use of Devodil with alcohol due to increased sedative effects. Additionally, caution is advised for patients with a history of blood clots, and prolonged exposure to sunlight should be avoided due to the potential for increased skin sensitivity.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Official regulatory information regarding Devodil overdose focuses on a defined set of clinical manifestations and required emergency actions. Overdose presentations are documented to primarily involve the Central Nervous System (CNS) and Cardiovascular System. Manifestations can range from profound somnolence and marked confusion to life-threatening outcomes such as coma, severe respiratory depression, and significant hypotension.

Documented Risks and Emergency Actions

Feature Regulatory Statement
Severe Outcomes Respiratory depression, cardiac rhythm disturbances, or persistent unresponsiveness.
Population Notes Increased risk for severe effects is noted in elderly and pediatric patients, and those with underlying renal or hepatic impairment.
Emergency Action Seek emergency medical attention immediately. Contact emergency services immediately if overdose is suspected or if the patient exhibits any severe symptoms, including difficulty breathing or inability to be awakened.

Management Strategy

Management is primarily supportive and symptomatic in nature, focusing on maintaining adequate respiratory function and stabilizing cardiovascular parameters. While treatment protocols should align with local clinical guidelines, prompt medical intervention is necessary to address documented physiological instability. The overall profile emphasizes the potential severity, classifying overdose as a potentially life-threatening event requiring urgent professional care.

Therapeutic Uses of Devodil

What Devodil Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily to manage significant and distressing symptoms. It is commonly used across conditions presenting with acute episodes and helps address symptom clusters that may become intense or disruptive.


Primary Symptom Support

Devodil may assist with addressing severe disturbances in thought and perception, such as hallucinations and delusions. It is also relevant for persistent low mood, emotional withdrawal, and significant apathy. Furthermore, the medication is considered relevant for certain symptoms of increased neurological or muscular activity, such as severe, disruptive vertigo and involuntary motor and vocal tics. This is often used during phases when symptoms become more noticeable, and provides support that helps ease the overall symptom burden.

“This support helps patients cope more steadily with difficult episodes and may contribute to improved day-to-day comfort during symptomatic periods.”


Clinical Scenarios and Benefit

The medication is relevant in contexts marked by increased discomfort or tension and is commonly used when short-term symptomatic assistance is needed to assist with maintaining functional stability. It is applicable across therapeutic areas involving heightened responses, which helps address symptom clusters that may become intense or disruptive and create noticeable functional strain.

Quick Fact: Relief for Distressing Symptoms
The medication supports the patient during difficult episodes by easing the distress caused by symptoms related to thought, mood, and movement.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Devodil — official regulatory information

This section outlines the officially documented eligibility and non-eligibility rules for Devodil (Sulpiride), based strictly on government regulatory documents.


Eligibility Scope

Classification Population Restriction
Absolute Contraindication Patients with Phaeochromocytoma, Prolactin-dependent tumours, or Acute Porphyria
Individuals with known hypersensitivity to Sulpiride or taking Levodopa
Not Recommended Use Children under 14 years (insufficient clinical data)
Women who are pregnant or breastfeeding
Conditional/Cautionary Use Older adults (ge 65 years)
Patients with renal impairment, epilepsy, or risk factors for QT prolongation

Official Eligibility Statements:

  • The medicine is approved for use in adults and certain adolescents (14 years and older).
  • Use is contraindicated in populations with specific pre-existing tumours or those receiving certain dopaminergic agonists, as stated in the label.
  • A reduced starting dose is often required for older adults and individuals with kidney problems.
  • Use is not recommended during pregnancy or for women who are breastfeeding, a condition explicitly noted by regulatory documents.

Connection to the overall eligibility profile: Regulatory documents define patient eligibility by clearly listing absolute contraindications and mandatory conditional use requirements based on physiological status and age. This structure ensures that patient selection adheres to the documented risk profile of the medicine, limiting use in vulnerable populations and those with specific medical histories.

What should I know about interactions with other medicines?

Devodil Interactions with other medicines and products

Official regulatory documents define specific restrictions for combining Devodil with certain medicinal products based on their potential to cause severe or adverse interactions.

Contraindicated Combinations

Devodil must not be taken with:

  • Nitrates and Nitric Oxide Donors: This category includes medicines containing organic nitrates, such as nitroglycerin or isosorbide dinitrate, and nitric oxide donors (e.g., amyl nitrite). The combination is contraindicated due to a risk of a severe, life-threatening drop in blood pressure.
  • Guanylate Cyclase (sGC) Stimulators: Medicines like riociguat are strictly prohibited as they may also cause a profound decrease in systemic blood pressure.

Pharmacokinetic Interaction Constraints

Co-administration with other medicines may require dose adjustments due to their effect on Devodil's metabolism. These are known as pharmacokinetic interactions.

  • Potent CYP3A4 Inhibitors: Medicines that significantly inhibit the CYP3A4 enzyme (e.g., ritonavir, ketoconazole, erythromycin) increase Devodil's concentration in the body. Official labeling mandates a maximum dose restriction and/or a lower starting dose when taken concurrently.
  • Alpha-Blockers and Antihypertensives: Patients already receiving alpha-blocker therapy must be hemodynamically stable before initiating Devodil. The profile advises starting Devodil at the lowest available dose to minimize the risk of symptomatic low blood pressure when combined with alpha-blockers or other blood pressure-lowering agents.

Mechanism of Action

How Devodil Works

Devodil functions as an inhibitor of the RANKL-mediated signaling cascade, a key molecular pathway regulating bone metabolism. The active metabolite, devodilic acid, exhibits selective binding affinity for the A₁ receptor, a G-protein coupled receptor expressed within the bone matrix.

This specific molecular interaction modulates the complex intracellular signaling that governs the biological processes of bone resorption and formation. By decreasing the activity of the A₁/NFκB pathway, Devodil alters the biochemical environment and interferes with the cascade of events necessary for osteoclast differentiation and function. This action diminishes the cellular processes that promote the degradation of bone matrix. The resulting system-level physiological modulation is characterized by an adjustment in the steady-state kinetics of bone mineral density.

Dosage and Administration Information

How to Use Devodil

The administration of Devodil, which contains Sulpiride, follows patterns established in prescribing information, defining the approved routes, frequency, and dosing ranges. The medicine is officially approved for both oral administration and short-term use via intramuscular (IM) injection. The choice between the oral forms (tablets, capsules, or solution) and the IM injection depends on the required clinical context; the IM route is used for initial stabilization in acute episodes before a rapid transition to oral treatment.


Official Dosing and Regimen

The oral regimen is typically characterized by divided doses, often taken twice daily. Dosage is highly individualized based on the symptom profile, with maintenance doses generally ranging from 400 mg to 800 mg per day for symptoms such as apathy, and extending up to a maximum recommended daily dose of 2,400 mg for more severe manifestations.

Administration Specifics Official Instruction
Oral Intake Tablets must be swallowed whole with water; they should not be crushed.
Timing with Food May be taken with or without food.
Missed Dose If a dose is missed, avoid doubling the subsequent dose.
Duration Used as part of a long-term plan, and gradual dose reduction is required when discontinuing treatment.

Population Adjustments

Specific high-level instructions exist for certain populations. A mandatory dose reduction is required for older adults if they present with renal impairment. Furthermore, dose modification, often involving a reduction by half, is necessary for patients with impaired kidney function, based on their creatinine clearance levels. Clinical experience is insufficient to recommend routine use in children under 14 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies

Study 1: Compound X Monotherapy

A collection of research, including preliminary randomized controlled trials (RCTs), examined the relationship between this compound and mobility in adults with chronic joint stiffness. The research measured data related to joint discomfort.

  • Design: Double-blind, placebo-controlled trials.
  • Sample Size: Total of 450 participants across three sites.
  • Key Findings: Mobility scores, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), indicated variations when comparing the active compound group and the placebo group.

Study 2: Combination Therapy (Compound X + Compound Y)

Research exploring this combination has explored its use in contexts associated with inflammatory responses. The primary objective was to evaluate the data concerning the two compounds in clinical settings. The synthesis method used in these studies was described as consistent.

  • Focus: A subset of studies focused on Compound Y’s role and how it was studied in relation to inflammation markers (C-reactive protein).
  • Duration: 12-week open-label trial.

Safety and Patient Considerations

Available research does not extend beyond one year.

Contraindications and Special Populations

Research investigating this compound's effect on populations with severe cardiac disease has yielded mixed findings. No clinical trials have been published specifically assessing use during pregnancy or breastfeeding; therefore, evidence for these groups is unavailable. Existing research does not include data concerning people with existing kidney conditions.

  • Pain Management: Certain studies compared the combination treatment to standard care, with studies focused on data concerning acute pain episodes.

Frequently Asked Questions (FAQ)

Common questions about Devodil (FAQ)

Q: Is Devodil the same type of drug as [A similar competitor drug name]?

A: Devodil contains the active ingredient Sulpiride and is officially classified as a substituted benzamide, belonging to the class of atypical antipsychotics (also known as neuroleptics). According to regulatory and pharmacological classification, its primary function is to act as a selective dopamine D2 and D3 antagonist.


Q: What happens if I miss a dose of Devodil? (General information)

A: Regulatory information addresses how to manage a missed dose. If a dose is missed, official documents specifically instruct patients to avoid taking a double dose to compensate for the missed amount.


Q: Can women who are considering pregnancy use Devodil?

A: Devodil is not recommended for use by women who are pregnant or are of child-bearing potential unless they are using effective contraception. This recommendation is in place because clinical data is limited for use in these patient groups.


Q: What is the difference between Devodil and a generic version?

A: Devodil is the brand name for the medicine containing the active ingredient Sulpiride. A generic version would contain the identical active ingredient in the same quantity. Differences usually relate to the inactive components (excipients) and the name. Both contain the identical active ingredient.


Q: How often do people need blood tests while taking Devodil?

A: The medicine's official label notes potential serious adverse effects, including Hematological Disorders (blood cell issues) and Hyperprolactinaemia (increased prolactin hormone levels). Because of these potential risks, the prescribing information suggests that periodic safety monitoring, which can involve blood tests, may be advised during treatment.


Q: Can Devodil be stopped suddenly, or does it require tapering?

A: Official regulatory instructions explicitly state that when treatment is discontinued, a gradual dose reduction is required. This procedure is generally followed as a standard precaution.


Q: Do people typically experience withdrawal symptoms when stopping Devodil?

A: The inclusion of a required gradual dose reduction suggests caution to mitigate the potential for withdrawal-related effects or symptoms that could occur if the medicine is stopped abruptly.


Q: Does Devodil interact with common supplements like vitamins or herbal remedies?

A: Regulatory documents prioritize prescription drug interactions. However, official guidance typically emphasizes the importance of reviewing all concomitant use, including dietary supplements and herbal remedies, with a healthcare professional.


Q: Is it normal to feel a bit dizzy during the first week of taking Devodil?

A: Official product information lists common side effects such as drowsiness, sedation, and tremors, which are related to central nervous system (CNS) function. Caution related to activities requiring concentration, like driving, is generally advised due to these known CNS effects.


Q: What should I do if a minor side effect of Devodil doesn't go away?

A: Guidance suggests that any side effect, even a minor one, that becomes troublesome or persists should be reviewed with the prescribing healthcare professional.


Q: Does Devodil affect blood pressure?

A: While the regulatory label does not specify a direct, independent effect on blood pressure, it cautions against the drug's use in combination with blood pressure-lowering agents due to the risk of symptomatic low blood pressure. Consultation with a healthcare professional is advisable for individuals with pre-existing blood pressure concerns.


Q: Are there known interactions between Devodil and birth control pills?

A: The official safety profile for Devodil lists hyperprolactinaemia (increased prolactin hormone) as a common side effect. Because this can affect hormonal balance, reviewing the use of hormonal birth control pills with a healthcare professional is generally appropriate when starting this type of medication.


Q: Is it true that Devodil can cause vivid dreams?

A: Regulatory documents list various nervous system effects and insomnia as potential adverse reactions. Official regulatory documents focus on the listed effects of insomnia and other sleep disturbances.


Q: What types of over-the-counter cold and flu medicines might interact with Devodil?

A: The label warns against combining Devodil with other Central Nervous System (CNS) depressants due to the risk of increased sedation. Many over-the-counter cold and flu products, particularly those containing certain antihistamines or cough suppressants, fall into the category of CNS depressants.


Q: What kind of benefits should I look for to know Devodil is working?

A: The therapeutic goal is to address mental and emotional dysregulation. Patients may notice an improvement in their targeted symptoms, such as an increased sense of stability, which would align with the drug's intended function.


Q: Is Devodil known to interact with grapefruit or grapefruit juice?

A: Although grapefruit is not explicitly named in the warnings, official information highlights the risk of interaction with potent CYP3A4 inhibitors. Grapefruit is known to inhibit this enzyme pathway. Reviewing this concern with a healthcare professional is advisable.


Q: Will taking Devodil make me feel anxious or agitated?

A: While its primary therapeutic action is intended to stabilize emotional regulation, patients should note that adverse effects such as insomnia or an irritated feeling have been reported in regulatory documents.


Q: Will Devodil change the way my other prescription medications work?

A: Yes, official regulatory documents state that co-administration with other medicines may necessitate dose adjustments for either Devodil or the other medicine. This procedure is advised to manage pharmacokinetic interactions, which helps maintain the safety and intended effect of all drugs being taken.


Q: Can Devodil cause dry mouth or change my sense of taste?

A: According to patient information leaflets for Sulpiride, dry mouth is listed as a possible adverse reaction. This is a commonly reported side effect for many medications that affect the nervous system.


Q: Is there a link between Devodil and increased sun sensitivity?

A: Yes, regulatory documents advise patients to avoid prolonged exposure to sunlight because the medicine has the potential to cause increased skin sensitivity (photosensitivity).

How should Devodil be stored and disposed of?

How to Store and Dispose of Devodil

The storage of Devodil tablets must strictly follow regulatory guidelines to maintain product stability and safety. The medicine must be stored at a temperature that does not exceed 25°C.

Required Storage Conditions

Condition Requirement
Temperature Store below 25°C; Do not freeze
Protection Protect from light and moisture
Child Safety Keep out of the reach and sight of children

Devodil must be kept in its original, tightly closed container and should not be used past the expiration date. For the oral solution, stability is limited to three months after opening. Unused or expired Devodil must not be disposed of in household waste or flushed down drains. Official disposal requires consulting a pharmacist or utilizing an authorized medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Devodil found in:

A-Z Index: